Fresenius Medical Care (NYSE:FMS) Sets New 12-Month High - Here's What Happened

Shares of Fresenius Medical Care AG (NYSE:FMS - Get Free Report) hit a new 52-week high on Thursday . The stock traded as high as $25.06 and last traded at $24.88, with a volume of 262765 shares. The stock had previously closed at $24.66.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on FMS. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research note on Friday, January 3rd. They issued a "strong-buy" rating on the stock. Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd. Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a "buy" rating and a $25.60 target price for the company. Finally, Truist Financial boosted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research note on Monday, January 6th.

Fresenius Medical Care Price Performance

The business has a 50 day simple moving average of $23.09 and a 200-day simple moving average of $21.15. The company has a market capitalization of $14.64 billion, a P/E ratio of 20.62, a PEG ratio of 0.75 and a beta of 0.92. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.42 by $0.03. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The firm had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.36 billion. During the same period in the previous year, the business posted $0.31 EPS. Analysts predict that Fresenius Medical Care AG will post 1.53 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care

Several hedge funds have recently added to or reduced their stakes in the business. ABC Arbitrage SA acquired a new position in shares of Fresenius Medical Care during the fourth quarter valued at $4,215,000. Autumn Glory Partners LLC acquired a new position in Fresenius Medical Care during the 4th quarter valued at about $208,000. Yousif Capital Management LLC acquired a new position in Fresenius Medical Care during the 4th quarter valued at about $208,000. DAVENPORT & Co LLC raised its position in shares of Fresenius Medical Care by 1.5% during the 4th quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock worth $1,316,000 after buying an additional 862 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Fresenius Medical Care by 15.6% in the 4th quarter. Blue Trust Inc. now owns 14,876 shares of the company's stock worth $317,000 after acquiring an additional 2,013 shares during the period. Institutional investors own 8.37% of the company's stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.